Novel Strategies to Detect and Arrest the Progression of Alzheimer’s Disease Early

Novel Strategies to Detect and Arrest the Progression of Alzheimer’s Disease Early is organized by Paradigm Medical Communications, LLC.

Release Date: April 12, 2024
Expiration Date: April 12, 2025

Description:
Managing the care of patients with AD is challenging for both PCPs and specialists. Available treatments have attempted to alleviate symptoms; however, a recently approved novel anti-amyloid therapy is the first to demonstrate a positive impact on both AD pathophysiology and disease progression—if applied early. Despite this groundbreaking advance, hurdles to implementing disease-modifying therapy remain, including diagnostic delays, use of biomarker assessments that establish treatment eligibility, and ongoing monitoring to detect potential adverse events. PCPs and specialists have unique roles in caring for this population, and are well positioned to identify and manage treatment-eligible patients appropriately.

Learning Objectives:
Upon completion of this activity, participants should be able to:

All Audiences

• Describe the natural history of AD in relation to the potential for disease modification with novel therapy
• Outline key efficacy and safety data related to novel and emerging therapies that target early-stage AD

AD Specialists

• Confirm a diagnosis of AD based on appropriate use and interpretation of biomarker assessments
• Demonstrate appropriate use of anti-amyloid therapy in patients with early symptomatic AD, such as appropriate patient selection, ongoing monitoring, and management of adverse events

PCPs

• Recognize patients who would benefit from further evaluation/specialist referral for potential AD, based on signs, symptoms, and risk factors
• Identify key points for education and counseling of patients who may be eligible for, or are already receiving, disease-modifying therapy for early-stage AD